DMD #19471

Introduction
Trazodone is a second-generation triazolopyridinone antidepressant drug (Scheme 1), which is structurally distinct from selective serotonin reuptake inhibitors, triand tetracyclics, and monoamine oxidase inhibitors. It is thought to act through combined 5-HT 2 antagonism and 5-HT reuptake blockage (Haria et al., 1994) . Trazodone is often co-prescribed with other antidepressants as a sleep-inducing agent because of its more sedating and less anticholinergic side effects. Despite its therapeutic benefits, treatment with trazodone has been associated with rare, but severe incidence of hepatic injury (Chu et al., 1983; Longstreth et al., 1985 , Beck et al., 1993 Hull et al., 1994) , which is often described as idiosyncratic toxicity. Although the exact mechanism of trazodone hepatotoxicity is not clearly understood, a probable causal link between trazodone use and the onset of hepatic injury has been established (Fernandes et al., 2000; Rettman et al., 2001) .
As shown in Scheme 1, trazodone contains a triazolopyridinone moiety and a 3-chlorophenylpiperazine ring system. In humans, trazodone undergoes extensive hepatic metabolism mainly by hydroxylation, N-dealkylation and N-oxidation (Baiocchi et al., 1974; Yamato et al., 1974; Jauch et al., 1976) . Of particular interest in the biotransformation pathways of trazodone in humans is the detection and characterization of a dihydrodiol metabolite and 4'-hydroxytrazodone as major metabolites in urine (Baiocchi et al., 1974; Jauch et al., 1976) . Formation of the dihydrodiol metabolite can presumably occur by nucleophilic addition of water to an electrophilic epoxide intermediate. On the other hand, 4'-hydroxytrazodone can undergo a two-electron oxidation leading to formation of an electrophilic quinone imine intermediate, which is DMD #19471 6 capable of reacting with cellular proteins and other nucleophiles such as glutathione (Scheme 1). In human liver microsomal incubations, two glutathione adducts have been previously identified (Kalgutkar et al., 2005a) arising from quinone imine and epoxide intermediates (M1 and M2 depicted in Scheme 1). The epoxidation of triazolopyridinone, para-hydroxylation of 3-chlorophenylpiperazine and subsequent oxidation to quinone imine were shown to be mediated by cytochrome P450 (CYP) 3A4 (Kalgutkar et al., 2005a) . These findings are significant as the first line of evidence to suggest that cytochromes P450-mediated reactive metabolites may play an important role in toxicity of the drug.
It is noteworthy that 1-(3'-chlorophenyl)piperazine (m-CPP, Scheme 1), resulting from N-dealkylation of trazodone, is a major circulating metabolite in humans common to several antidepressants including trazodone, nefazodone and etoperidone (Otani et al., 1997; von Moltke et al., 1999; Melzalka et al., 1980; Fong et al., 1982) . The metabolite m-CPP is of significant interest because it has 5-HT 2C agonistic and 5-HT 2A antagonistic
properties (Conn and Sanders-Bush, 1987; Fiorella et al., 1995) . It has also been suggested that m-CPP may contribute to the antidepressant efficacy of trazodone (Maes et al., 1997) . While oxidative metabolism of trazodone, nefazodone and etoperidone are controlled by CYP3A4 (Zalma, et al., 2000; Rotzinger et al., 1998a; von Moltke et al., 
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Microsomal Incubations. All incubations were performed at 37°C in a water bath. Stock solutions of the test compounds were prepared in methanol. The final concentration of methanol in the incubation was 0.2% (v/v) . Pooled HLMs and the human cDNA-expressed P450 isozymes were carefully thawed on ice prior to the experiment. Trazodone, nefazodone, m-CPP or p-CPP (10 µ M) was individually mixed with HLM proteins (1 mg/ml) in 100 mM potassium phosphate buffer (pH 7.4) supplemented with 1 mM GSH. The total incubation volume was 1 mL. After 3 min preincubation at 37°C, the incubation reactions were initiated by the addition of 1 mM NADPH. Reactions were terminated by the addition of 150 µ L of trichloroacetic acid (10%) after 60 min incubation. Incubations with the recombinant cDNA-expressed P450
isozymes were performed similarly except that liver microsomes were substituted by Supersomes TM (100 pmol/ml). Control samples containing no NADPH or substrates were included. Samples were centrifuged at 10,000 g for 15 min at 4°C to pellet the precipitated proteins, and supernatants were subjected to LC/MS/MS analysis of GSH adducts. Each incubation was performed in triplicate. For the negative precursor ion scanning of GSH adducts, supernatants were concentrated by solid phase extraction as described below, prior to LC/MS/MS analyses. For concentration-dependent inhibition, the specific CYP2D6 inhibitor quinidine was used to further access the role of CYP2D6 for the reactive metabolite formation from incubations of m-CPP in human liver microsomes. Under similar incubation conditions described above, quinidine at various concentrations (0, 0.1, 0.3, 0.7, 1.2, 2, 4 or 6 µ M) was added to the incubation mixture containing m-CPP (50 µ M).
P450 Inhibition by Chemical Inhibitors.
DMD #19471 with 2 ml methanol and then conditioned with 2 ml of water. Supernatants resulting from centrifugation were loaded onto the cartridges, and cartridges were washed with 2 ml of water and then eluted with 2 ml of methanol. The methanol fractions were dried by nitrogen gas and reconstituted with 100 µ l of a water-methanol (70:30) mixture. Aliquots (20 µ l) of the reconstituted solutions were subjected to LC/MS/MS analysis. Molecular Modeling. The structure of m-CPP was drawn and the geometry was optimized using the NDDO (neglect of diatomic differential overlap) semiempirical method of PM3 by steepest decent (Stewart, 2004; Pople and Segal, 1965) with ArgusLab 4.0 (Planaria Software, Seattle, WA). This was aligned and edited into the active site of the X-ray crystal structure of CYP2D6 (Protein Data Bank code: 2F9Q) (Rowland et al., 2006) . The structure was manipulated using WebLab Viewer Lite 4.0 (Accelrys, San Diego, CA) and ArgusLab 4.0, so that it was orientated in a geometrically reasonable position with no significant Van der Waals overlap with the protein, providing us a working model of the m-CPP bound CYP2D6.
LC/MS/MS
Results
Characterization of GSH Adducts of Trazodone. For the LC/MS/MS analysis of GSH adducts, samples generated from incubations with human liver microsomes were desalted and concentrated by solid-phase extractions, and resulting samples were subjected to the PI-EPI experiments. MS detection was carried out using the negative precursor ion scanning of m/z 272, corresponding to deprotonated γ -glutamyldehydroalanyl-glycine originating from the glutathionyl moiety (Dieckhaus et al., 2005) .
MS/MS spectra were acquired in positive ion mode using information-dependent data acquisition (Hopfgartner et al., 2003) . As shown in Fig. 1A , a total of seven major components were detected by the negative precursor ion scanning of m/z 272 and they were arbitrarily designated as M1 (10.9 min), M2 (12.7 min), M3 (6.0 min), M4 (8.0 This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 1A) . Also the MS/MS spectra of these components were essentially identical as those of the corresponding GSH adducts from the trazodone incubation with HLMs or recombinant CYP2D6 (Fig. 2, Fig. 3 and Fig 1C) . These data confirmed the structural identities of m-CPP derived GSH adducts formed in the incubations of This article has not been copyedited and formatted. The final version may differ from this version. trazodone. Under the same incubation conditions, the regioisomer p-CPP showed no bioactivation in human liver microsomes (Fig. 1D) . The blockage of bioactivation of p-CPP was also confirmed by NL scanning of m/z 129 and 75, respectively (data not shown). In the incubations of trazodone, formation of M1, M2 and M4 was examined.
GSH
Consistent with observations by others (Kalgutkar et al., 2005a) , it was found that formation of M1 and M2 was primarily mediated by CYP3A4, and to a less extent by CYP3A5 (Fig. 6B ). CYP2D6 also catalyzed formation of M1 and M2, but both levels were less than 10% of those formed by CYP3A4. No single P450 isozyme was capable of catalyzing formation of M4 from the incubations of trazodone (Fig. 6B ). This result agrees well with a previous report that the N-dealkylation of trazodone to form m-CPP was primarily mediated by CYP3A4 (Rotzinger, 1998a) . In marked contrast, the formation of M4 was dramatically increased in the presence of both CYP2D6 and CYP3A4 (Fig. 6B) . These data clearly suggested that while bioactivation and N- compared to the control value. This can be explained by the inhibition of CYP3A4-dependent N-dealkylation of trazodone (Rotzinger, 1998a) . Quinidine, a specific CYP2D6 inhibitor, strongly inhibited M4 formation by 83%, but did not inhibit the formation of M1 and M2 (Table 1 ).
In the incubations of m-CPP, formation of M4 was only inhibited by quinidine, which is consistent with the predominant role of CYP2D6 for M4 formation in the incubations with recombinant P450s. In both incubations of trazodone and m-CPP, the inhibitory effects on the formation of M1, M2 and M4 were minimal (<10%) for other P450 specific inhibitors including α -naphthoflavone (CYP1A2), sulfaphenazole (CYP2C9) and tranylcypromine (CYP2C19) ( Table 1) . It is noteworthy to point out that ketoconazole did not inhibit the formation of M4 from m-CPP (<10% inhibition). Unlike M4 and M5, M3 was identified as a GSH adduct of m-CPP containing no chlorine atom. Recently, a similar deschloro GSH adduct of diclofenac was identified by LC/MS/MS and NMR and proposed to be derived from an ipso substitution of chlorine by GSH from a quinone imine intermediate (Yu et al., 2005) . Because the proposed ipso substitution pathway is a two-step oxidation pathway and requires a initial oxidation on the C-4' position, we further investigated the metabolic mechanisms using a regioisomer which is shared by M4 and M5, followed by the ipso substitution by GSH (Scheme 2).
Concentration-dependent
Similarly, the structure of M6 is proposed to be 4'-hydroxy-3'-(glutathione-S-yl)-deschloro-trazodone. Both proposed structures would have expected fragmentation patterns consistent with the CID MS/MS spectra ( Fig. 3B and 4B, respectively ). An alternate pathway for deschloro adduct formation is P450-mediated epoxidation between the C-3' and C-4' or the C-3' and C-2' positions on the chlorophenyl ring. Loss of chlorine would result from an attack of GSH on the epoxide. This mechanism has been proposed for the formation of the deschloro GSH adduct of diclofenac in human liver microsomal incubations (Yan et al., 2005) . While the current study cannot rule out this bioactivation pathway, one would expect that such potential epoxides could be formed in incubations of the regioisomer of m-CPP, p-CPP, for example, an epoxide between the C-4' and C-3'
positions. The formed epoxides can readily be trapped by GSH to afford corresponding conjugates. However, both PI and NL scans failed to detect any GSH adducts in the incubations of p-CPP.
Our structural modeling of the CYP2D6-m-CPP complex revealed a well defined binding mode of m-CPP, with its orientation precisely controlled by a hydrophobic π -π interaction with Phe-120 at the bottom and an ionic hydrogen bond with Glu-216 from the top (Fig. 8) . confirm the absolute structures of these newly detected GSH adducts using synthetic standards. However, efforts to synthesize M3 and M6 have currently been hampered by the lack of a feasible chemistry strategy. Attempts were made to isolate M3 and M6
directly from incubations of trazodone with HLMs using preparative LC, but failed to obtain enough of the adducts in the desired purity for NMR analysis, due to the low abundance of GSH adducts formed in the incubations. Regardless, formation of M3 and M6 represents unique reactive metabolites formed by trazodone.
Apart from CYP3A-mediated M1 and M2 formation, the formation of M4 from m-CPP was found to be mediated specifically by CYP2D6. This conclusion is supported 
